These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33147322)

  • 1. 4-1BB (CD137) in anticancer chimeras.
    Melero I; Berraondo P
    J Exp Med; 2020 Dec; 217(12):. PubMed ID: 33147322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.
    Chacon JA; Wu RC; Sukhumalchandra P; Molldrem JJ; Sarnaik A; Pilon-Thomas S; Weber J; Hwu P; Radvanyi L
    PLoS One; 2013; 8(4):e60031. PubMed ID: 23560068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis.
    Etxeberria I; Glez-Vaz J; Teijeira Á; Melero I
    ESMO Open; 2020 Jul; 4(Suppl 3):e000733. PubMed ID: 32611557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD137 monoclonal antibodies and adoptive T cell therapy: a perfect marriage?
    Weigelin B; Bolaños E; Rodriguez-Ruiz ME; Martinez-Forero I; Friedl P; Melero I
    Cancer Immunol Immunother; 2016 May; 65(5):493-7. PubMed ID: 26970765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.
    Weigelin B; Bolaños E; Teijeira A; Martinez-Forero I; Labiano S; Azpilikueta A; Morales-Kastresana A; Quetglas JI; Wagena E; Sánchez-Paulete AR; Chen L; Friedl P; Melero I
    Proc Natl Acad Sci U S A; 2015 Jun; 112(24):7551-6. PubMed ID: 26034288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
    Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
    J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma.
    Fröhlich A; Loick S; Bawden EG; Fietz S; Dietrich J; Diekmann E; Saavedra G; Fröhlich H; Niebel D; Sirokay J; Zarbl R; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
    EBioMedicine; 2020 Feb; 52():102647. PubMed ID: 32028068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy.
    Sanchez-Paulete AR; Labiano S; Rodriguez-Ruiz ME; Azpilikueta A; Etxeberria I; Bolaños E; Lang V; Rodriguez M; Aznar MA; Jure-Kunkel M; Melero I
    Eur J Immunol; 2016 Mar; 46(3):513-22. PubMed ID: 26773716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells.
    Mardiana S; John LB; Henderson MA; Slaney CY; von Scheidt B; Giuffrida L; Davenport AJ; Trapani JA; Neeson PJ; Loi S; Haynes NM; Kershaw MH; Beavis PA; Darcy PK
    Cancer Res; 2017 Mar; 77(6):1296-1309. PubMed ID: 28082401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strong induction of 4-1BB, a growth and survival promoting costimulatory receptor, in HTLV-1-infected cultured and patients' T cells by the viral Tax oncoprotein.
    Pichler K; Kattan T; Gentzsch J; Kress AK; Taylor GP; Bangham CR; Grassmann R
    Blood; 2008 May; 111(9):4741-51. PubMed ID: 18276843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy.
    Oda SK; Anderson KG; Ravikumar P; Bonson P; Garcia NM; Jenkins CM; Zhuang S; Daman AW; Chiu EY; Bates BM; Greenberg PD
    J Exp Med; 2020 Dec; 217(12):. PubMed ID: 32860705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1 abrogates the prolonged persistence of CD8
    Li F; Zhang Z; Xuan Y; Zhang D; Liu J; Li A; Wang S; Li T; Shi X; Zhang Y
    Signal Transduct Target Ther; 2020 Aug; 5(1):164. PubMed ID: 32843615
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB.
    Li S; Zhang J; Wang M; Fu G; Li Y; Pei L; Xiong Z; Qin D; Zhang R; Tian X; Wei Z; Chen R; Chen X; Wan J; Chen J; Wei X; Xu Y; Zhang P; Wang P; Peng X; Yang S; Shen J; Yang Z; Chen J; Qian C
    Br J Haematol; 2018 May; 181(3):360-371. PubMed ID: 29637550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs.
    Zapata JM; Perez-Chacon G; Carr-Baena P; Martinez-Forero I; Azpilikueta A; Otano I; Melero I
    Front Immunol; 2018; 9():2618. PubMed ID: 30524423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.
    Milone MC; Fish JD; Carpenito C; Carroll RG; Binder GK; Teachey D; Samanta M; Lakhal M; Gloss B; Danet-Desnoyers G; Campana D; Riley JL; Grupp SA; June CH
    Mol Ther; 2009 Aug; 17(8):1453-64. PubMed ID: 19384291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-1BB chimeric antigen receptors.
    Campana D; Schwarz H; Imai C
    Cancer J; 2014; 20(2):134-40. PubMed ID: 24667959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD137 Suppresses Tumor Growth by Blocking Reverse Signaling by CD137 Ligand.
    Kang SW; Lee SC; Park SH; Kim J; Kim HH; Lee HW; Seo SK; Kwon BS; Cho HR; Kwon B
    Cancer Res; 2017 Nov; 77(21):5989-6000. PubMed ID: 28923858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology.
    Koristka S; Kegler A; Bergmann R; Arndt C; Feldmann A; Albert S; Cartellieri M; Ehninger A; Ehninger G; Middeke JM; Bornhäuser M; Schmitz M; Pietzsch J; Akgün K; Ziemssen T; Steinbach J; Bachmann MP
    J Autoimmun; 2018 Jun; 90():116-131. PubMed ID: 29503042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2
    Dai Q; Han P; Qi X; Li F; Li M; Fan L; Zhang H; Zhang X; Yang X
    Front Immunol; 2020; 11():539654. PubMed ID: 33281809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy of cancer with 4-1BB.
    Vinay DS; Kwon BS
    Mol Cancer Ther; 2012 May; 11(5):1062-70. PubMed ID: 22532596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.